Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04889716 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CAR-T Followed by Bispecific Antibodies

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint removed 2 → 1 primary endpoints
See other at-risk trials from Abramson Cancer Center at Penn Medicine

Record History

  1. Primary endpoint(s) modified Enrollment closed, study ongoing · Site details revised at 2 of 2 sitesv13 Show 2 more changesShow less
    • Enrollment closed, study ongoing
    • Site details revised at 2 of 2 sites

    See this version in full on ClinicalTrials.gov ↗

  2. Primary endpoint(s) modified Enrollment reduced: 42 → 23 participants · Eligibility criteria shortened, about 32 words · Site contacts updated at 1 of 2 sitesv12 Show 3 more changesShow less
    • Enrollment reduced: 42 → 23 participants
    • Eligibility criteria shortened, about 32 words
    • Site contacts updated at 1 of 2 sites

    See this version in full on ClinicalTrials.gov ↗

  3. Primary completion date: Jun 30, 2026 to Dec 31, 2027 Completion date: Jun 30, 2027 to Dec 31, 2028v11 Show 1 more changeShow less
    • Completion date: Jun 30, 2027 to Dec 31, 2028
  4. Primary completion date: Dec 31, 2024 to Jun 30, 2026 Completion date: Dec 31, 2025 to Jun 30, 2027v10 Show 1 more changeShow less
    • Completion date: Dec 31, 2025 to Jun 30, 2027
  5. Study sites: 1 to 2v9
Show 7 earlier versionsHide 7 earlier versions
  1. Eligibility criteria shortened, about 6 wordsv8 See this version in full on ClinicalTrials.gov ↗
  2. Eligibility criteria shortened, about 3 wordsv7 See this version in full on ClinicalTrials.gov ↗
  3. Primary completion date: Dec 31, 2023 to Dec 31, 2024v6
  4. Eligibility criteria expanded, about 7 wordsv5 See this version in full on ClinicalTrials.gov ↗
  5. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Nov 1, 2021 to Nov 5, 2021 · Site details revisedv4 Show 2 more changesShow less
    • Start date changed from estimate of Nov 1, 2021 to Nov 5, 2021
    • Site details revised
  6. Start date: Aug 15, 2021 to Nov 1, 2021v3
  7. Start date: May 15, 2021 to Aug 15, 2021v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The research study is being conducted to test the safety and effectiveness of the experimental drug mosunetuzumab (Cohort 1) or obinutuzumab and glofitamab (Cohort 2) when given after CAR (genetically modified) T cells. The study is for patients who have already received a CAR T-cell infusion. Some patients who join the study will receive mosunetuzumab, other patients later in the study may receive a different experimental drug (glofitamab, in combination with obinutuzumab).
Trial Details
NCT Number NCT04889716
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Genentech, Inc.
Conditions Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
Enrollment 23 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov